U.S. Markets closed
  • S&P 500

    +15.87 (+0.34%)
  • Dow 30

    -60.10 (-0.17%)
  • Nasdaq

    +72.14 (+0.45%)
  • Russell 2000

    -13.42 (-0.56%)
  • Gold

    -0.20 (-0.01%)
  • Silver

    -0.02 (-0.08%)

    -0.0006 (-0.0568%)
  • 10-Yr Bond

    -0.0150 (-0.94%)
  • Vix

    +0.48 (+2.81%)

    -0.0003 (-0.0216%)

    +0.0520 (+0.0455%)

    +769.48 (+1.42%)
  • CMC Crypto 200

    -65.80 (-4.48%)
  • FTSE 100

    -35.24 (-0.48%)
  • Nikkei 225

    +84.43 (+0.29%)

Biotech Stocks on the Move

HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotech has been one of the hottest sectors this month. Investors are intrigued by the increase in M&A. Now's a great time to start researching some oversold issues.

Today we are highlighting: Delcath Systems, Inc. (DCTH), ZIOPHARM Oncology, Inc. (ZIOP), Tyme Technologies, Inc. (TYME), TRACON Pharmaceuticals, Inc. (TCON), and MannKind Corporation (MNKD).

An interventional oncology company focused on treating liver cancers with major upside potential, Delcath Systems, Inc. (DCTH) (Market Cap: $2.602M, Share Price: $0.2670), has had quite a year. They announced their Phase 3 clinical trial, raised $7 million, increased revenue 20% Y/Y, and were published in European Radiology among several other milestones.

The company made big news recently entering a licensing agreement for CHEMOSAT® commercialization in Europe with medac Gesellschaft für klinische Spezialpräparate mbH (medac). The agreement has a projected value of up to $45 million over the first seven-year term and includes an optional five-year extension. Medac is a privately held, multi-national pharmaceutical company based in Hamburg area, Germany. Founded in 1970, medac specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases. The company has offices globally, worldwide partner agreements in over 90 countries, and approximately 1,200 employees.

This comes on the heels of an announcement about the independent Data Safety Monitoring Board (DSMB) of the Registration trial for Patients with Hepatic Dominant Ocular Melanoma (The FOCUS Trial) completed another pre-specified review of safety data for treated patients in the trial. This review was conducted on data collected from both the prior randomized protocol and the amended single-arm protocol for the FOCUS Trial. The DSMB again recommended continuation of the study without modification.

ZIOPHARM Oncology, Inc. (ZIOP) (Market Cap: $320.558M, Share Price: $2.27)recently posted a letter to shareholders highlighting their 2018 milestones. Including the elimination of $157 million in debt which helped pave the way for the company to raise $50 million in a private placement from existing investors.

Tyme Technologies, Inc. (TYME) (Market Cap: $248.688M, Share Price: $2.41)announced that it will present clinical data from the Company's lead candidate, SM-88, at the 2019 ASCO Genitourinary Cancers Symposium, which will be held February 14-16, 2019 at the Moscone West Building in San Francisco, CA. Tyme will present data that were co-authored by investigators affiliated with the Albert Einstein College of Medicine Montefiore Medical Center and the University of California San Francisco.

TRACON Pharmaceuticals, Inc. (TCON) (Market Cap: $28.676M, Share Price: $0.96) developing novel therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, initiated a Phase 1 trial based on the potentiation of PD-1 checkpoint inhibition observed with TRC105 in pre-clinical models. The company found TRC105 was well-tolerated with Opdivo. The company expects to present data from the expansion cohorts in mid-2019.

MannKind Corporation (MNKD) (Market Cap: $240M, Share Price: $1.41)announced a direct purchase program to help those with diabetes obtain the company's inhaled insulin, Afrezza, for as little as $4 a day. Afrezza (insulin human) Inhalation Powder is a rapid-acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus.

Legal Disclaimer:

This article was written by Regal Consulting, LLC ("Regal Consulting"). Regal Consulting has agreed to a twelve-month term consulting agreement with DCTH dated 8/31/18. The agreement calls for $40,000 in cash, and 15,000 restricted 144 shares of DCTH per month. Issuer agreed to increase monthly cash payment in September to $120,000. All payments were made directly by Delcath Systems, Inc. to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspecultors.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. DCTH was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.

http://www.regalconsultingllc.com/full legal disclaimer/

Microspeculators.com Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators

Contact Person: Media Manager

Email: info@microcapspeculators.com

Phone: 1-702-720-6310

Country: United States

Website: http://microcapspeculators.com/

SOURCE: Regal Consulting, LLC